The aim of the study was to identify risk factors associated with severe infections in participants of the RAVE trial, including the impact of different prophylactic measures to prevent PJP, and the changes of immune cell subsets (‘immunocompetence’, ie, CD19+ cells at baseline and repopulation after therapy) on the risk to develop serious infectious complications. This evidence concerns the gene CD19 and infection.